Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.63 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.63 |
| ▸ | PDE1A | P54750 | 1/20 | 0.61 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.61 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | UBE2N | P61088 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | CNOT7 | Q9UIV1 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6346960 | 1.00 | POLB (0.69) | POLBHIF1ASMN1; SMN2ADORA2BRXFP1 | |
| SCHEMBL681897 | 1.00 | POLB (0.69) | POLBHIF1ASMN1; SMN2ADORA2BRXFP1 | |
| SCHEMBL4708439 | 0.86 | POLB (0.62) | POLBHIF1ASMN1; SMN2ADORA2BRXFP1 | |
| SCHEMBL4708433 | 0.86 | POLB (0.62) | POLBHIF1ASMN1; SMN2ADORA2BRXFP1 | |
| SCHEMBL6356193 | 0.86 | POLB (0.62) | POLBHIF1ASMN1; SMN2ADORA2BRXFP1 | |
| SCHEMBL2793931 | 0.85 | POLB (0.75) | POLBHIF1ASMN1; SMN2ADORA2BRXFP1 | |
| SCHEMBL3116289 | 0.85 | POLB (0.86) | POLBHIF1ASMN1; SMN2ADORA2BRXFP1 | |
| SCHEMBL11611142 | 0.85 | LMNA (0.58) | POLBSMN1; SMN2ADORA2BRXFP1TSHR | |
| SCHEMBL14985852 | 0.85 | LMNA (0.58) | POLBSMN1; SMN2ADORA2BRXFP1TSHR | |
| SCHEMBL7558870 | 0.84 | LMNA (0.71) | POLBHIF1ASMN1; SMN2ADORA2BRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130122050-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | DIAKINE THERAPEUTICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130122050-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | DIAKINE THERAPEUTICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20110052625-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | DIAKINE THERAPEUTICS, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110052625-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | DIAKINE THERAPEUTICS, INC. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20090269313-A1 | ENCAPSULATION SYSTEM | DIAKINE THERAPEUTICS, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090269313-A1 | ENCAPSULATION SYSTEM | DIAKINE THERAPEUTICS, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20080300189-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING BETA-CELL MASS AND FUNCTION | DIAKINE THERAPEUTICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300189-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING BETA-CELL MASS AND FUNCTION | DIAKINE THERAPEUTICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| WO-2008011518-A2 | ENCAPSULATION SYSTEM | DIAKINE THERAPEUTICS, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2006074051-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING β-CELL MASS AND FUNCTION | DIAKINE THERAPEUTICS, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
| EP-1171442-B1 | XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALLING INHIBITORS | CELL THERAPEUTICS INC (US) | 2005-12-07 | — | — | EP | disclosed |
| US-6878715-B1 | Therapeutic compounds for inhibiting interleukin-12 signals and method for using same | CELL THERAPEUTICS, INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-20050049262-A1 | Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same | CELL THERAPEUTICS, INC. (US) | 2005-03-03 | — | — | US | disclosed |
| US-20050032748-A1 | Substituted 2,5-dioxopurines, 2H-1,2,3-triazolyl[4,5-d]pyrimidines, or 1,2,5-thadiazolyl[3,4-d]pyrimidines; antiproliferative, antiinflammatory, and antiarthritic agents; psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, lupus, graft versus host disease | CELL THERAPEUTICS, INC. (US) | 2005-02-10 | — | — | US | disclosed |
| US-6774130-B2 | TREATING CHRONIC INFLAMMATORY DISEASE, CHRONIC INTESTINAL INFLAMMATION, ARTHRITIS, PSORIASIS, ASTHMA AND AUTOIMMUNE DISORDERS; TH1 CELL-MEDIATED DISORDERS; FOR EXAMPLE, 1,2,3,6-TETRAHYDRO-7H-PURINE-2,6-DIONE DERIVATIVES | CELL THERAPEUTICS, INC. | 2004-08-10 | — | — | US | disclosed |
| US-20020028823-A1 | THERAPEUTIC COMPOUNDS FOR INHIBITING INTERLEUKIN-12 SIGNALING AND METHODS FOR USING SAME | CELL THERAPEUTICS, INC. | 2002-03-07 | — | — | US | disclosed |
| EP-1171442-A1 | XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALLING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000061583-A1 | XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALING INHIBITORS | CELL THERAPEUTICS, INC. (US) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130122050-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | IAPP, LITAF, IGF2BP1 | POLB 2420/4885HIF1A 1186/4885SMN1; SMN2 1879/4885 |
| US-20050032748-A1 | Substituted 2,5-dioxopurines, 2H-1,2,3-triazolyl[4,5-d]pyrimidines, or 1,2,5-thadiazolyl[3,4-d]pyrimidines; antiproliferative, antiinflammatory, and antiarthritic agents; psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, lupus, graft versus host disease | TPMT, IL2, NFATC1 | POLB 1573/4885HIF1A 1804/4885SMN1; SMN2 1025/4885 |
| US-20110052625-A1 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE | IAPP, LITAF, IGF2BP1 | POLB 1843/4885HIF1A 1457/4885SMN1; SMN2 2079/4885 |
| US-20020028823-A1 | THERAPEUTIC COMPOUNDS FOR INHIBITING INTERLEUKIN-12 SIGNALING AND METHODS FOR USING SAME | CCR10, IL1RN, CCR1 | POLB 4651/4885HIF1A 3171/4885SMN1; SMN2 3624/4885 |
| US-20090269313-A1 | ENCAPSULATION SYSTEM | GPR119, IAPP, LIPA | POLB 4757/4885HIF1A 2176/4885SMN1; SMN2 2140/4885 |
| US-20050049262-A1 | Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same | IL2, CCR10, CCR1 | POLB 4754/4885HIF1A 3123/4885SMN1; SMN2 2827/4885 |
| US-20080300189-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING BETA-CELL MASS AND FUNCTION | IAPP, PNLIP, AMY2A | POLB 2923/4885HIF1A 2523/4885SMN1; SMN2 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.